What is the recommended approach when switching from fluoxetine (Prozac) to a Monoamine Oxidase Inhibitor (MAOI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Switching from Fluoxetine to an MAOI

STOP fluoxetine and wait 5 weeks prior to starting a MAOI 1.

Rationale for the 5-Week Washout Period

The extended washout period is mandated by fluoxetine's pharmacokinetic profile:

  • Fluoxetine has an extremely long elimination half-life, and its active metabolite norfluoxetine has an even longer half-life, requiring at least 5 weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) after stopping fluoxetine before starting an MAOI 1.

  • Complete clearance of both fluoxetine and norfluoxetine is essential to prevent life-threatening serotonin syndrome when initiating MAOI therapy 2.

Why Other Options Are Incorrect and Dangerous

5-7 Days Is Inadequate

  • A 5-7 day washout is appropriate for most antidepressants (those with shorter half-lives like sertraline, paroxetine, or citalopram), but fluoxetine is the critical exception due to its uniquely long half-life 3.

  • Starting an MAOI within 10 days of stopping fluoxetine resulted in a very high incidence of adverse effects, especially serotonin syndrome characterized by mental status changes (hypomania, confusion), myoclonus, hypertension, tremor, and diarrhea 4.

Starting MAOI First Is Contraindicated

  • Fluoxetine should never be used in combination with an MAOI, as there have been reports of serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability with rapid fluctuations of vital signs, and mental status changes progressing to delirium and coma 1.

  • Seven of eight clinical cases reviewed where an MAOI was initiated shortly after discontinuing fluoxetine resulted in fatal outcomes, with only one patient surviving after cyproheptadine therapy 5.

Cross-Tapering Is Absolutely Contraindicated

  • Cross-tapering involves overlapping administration of both medications, which creates the exact scenario that causes serotonin syndrome and is explicitly contraindicated by FDA labeling 1.

  • The combination of fluoxetine and MAOIs presents features resembling neuroleptic malignant syndrome and can result in hypermetabolic states involving serotonin and serotonin-dopamine interactions 5.

Clinical Monitoring During the Washout Period

  • Monitor for depressive symptom exacerbation during the 5-week medication-free period, as this represents a significant clinical challenge requiring close observation 3.

  • Educate patients about the rationale for the extended washout to ensure adherence, as premature MAOI initiation carries mortality risk 5.

  • Consider bridging strategies such as supportive psychotherapy or non-pharmacologic interventions during the washout period, though no serotonergic medications can be added 2.

Common Pitfalls to Avoid

  • Never assume fluoxetine behaves like other SSRIs when calculating washout periods—it is pharmacokinetically distinct and requires special consideration 1, 3.

  • Do not rely on symptom resolution as an indicator that fluoxetine has cleared; the 5-week period is based on pharmacokinetics, not clinical response 1.

  • Avoid any serotonergic medications during the washout, including tramadol, meperidine, dextromethorphan, St. John's Wort, or triptans, as these can precipitate serotonin syndrome even without an MAOI present 6, 2.

References

Guideline

Restarting Antidepressants After Serotonin Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Research

Adverse consequences of fluoxetine-MAOI combination therapy.

The Journal of clinical psychiatry, 1990

Guideline

Serotonin Syndrome Risk with Lamotrigine and Zonisamide

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.